MONEY

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 13, 2024 - 08:00
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Read More

Tags:

Previous Article

Marc Andreessen's funds sell over $14 million in Samsara stock

Next Article

Protagonist Therapeutics director Waddill sells $360,000 in stock

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Trump says no state would be allowed to ban gasoline-powered cars if he is elected

Trump says no state would be allowed to ban gasoline-po...

Tomas Kauer - Mode... Oct 4, 2024

Blinken subpoenaed to appear next week before House committee over Afghanistan

Blinken subpoenaed to appear next week before House com...

Tomas Kauer - Mode... Sep 19, 2024

Mazda to open new R&D office in Azabudai Hills in early summer 2025

Mazda to open new R&D office in Azabudai Hills in early...

Tomas Kauer - Mode... Sep 24, 2024